Abstract
The optimal management of patients with relapsed chronic lymphocytic leukemia (CLL) is dictated by the type of prior therapy, duration of prior response, presence of genomic aberrations, age, and comorbidities. The patterns of relapses and the clinical outcomes of second-line options after fludarabine-cyclophosphamide-rituximab (FCR) is given as a frontline treatment are currently unknown. In this retrospective and non-randomized study, we report the outcomes of 132 patients from databases of 14 French CLL study group centers who needed a second-line treatment after FCR frontline. Bendamustine + rituximab (BR) was the most frequently used second-line regimen, followed by alemtuzumab-based regimens, R-CHOP, and FCR. Median progression-free survival (PFS) was 18 months after BR with a median overall survival (OS) not reached. We also found that response durations of < 36 months and the presence of del(17p) are critical factors that contribute to poor overall survival. BR appears to be an effective salvage regimen in our series, both in terms of progression-free and overall survival. Patients who relapsed less than 36 months after FCR have a poor outcome, not significantly different in this study from patients with early relapses ...Continue Reading
References
Nov 17, 2006·Leukemia·P DregerUNKNOWN Chronic Leukemia Working Party of the EBMT
Oct 5, 2010·Lancet·M HallekUNKNOWN German Chronic Lymphocytic Leukaemia Study Group
Aug 17, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Kirsten FischerClemens-Martin Wendtner
Oct 20, 2011·Annals of Oncology : Official Journal of the European Society for Medical Oncology·B EichhorstUNKNOWN ESMO Guidelines Working Group
Dec 14, 2011·Hematology·Jennifer R Brown
Mar 20, 2013·European Journal of Haematology·Anna PanovskáMichael Doubek
May 2, 2013·Leukemia & Lymphoma·Paula CramerKirsten Fischer
Nov 14, 2013·Leukemia·A CortelezziR Foà
Jan 24, 2014·The New England Journal of Medicine·Richard R FurmanSusan M O'Brien
Jun 3, 2014·The New England Journal of Medicine·John C ByrdUNKNOWN RESONATE Investigators
Oct 5, 2014·Blood·Constantine S TamMichael J Keating
Citations
Dec 8, 2015·The New England Journal of Medicine·Andrew W RobertsJohn F Seymour
Jul 24, 2015·American Journal of Hematology·Mariarita SciumèAgostino Cortelezzi
Jun 30, 2015·Bulletin du cancer·Catherine Thieblemont
Jun 14, 2016·British Journal of Haematology·David J M Routledge, Adrian J C Bloor
Aug 16, 2016·Clinical Lymphoma, Myeloma & Leukemia·Emili Montserrat, Peter Dreger
Nov 4, 2016·Leukemia & Lymphoma·Davide RossiGeorg Stüssi
Nov 4, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Stephen Opat, Eliza A Hawkes
Jul 17, 2018·British Journal of Haematology·Anna H SchuhPeter Hillmen
Jun 28, 2018·European Journal of Haematology·Erel JoffeUNKNOWN Israeli CLL Study Group
Mar 1, 2019·Cancer Science·Wataru MunakataKensei Tobinai
May 10, 2019·Journal of Personalized Medicine·Maria KolesnikovaMarina Zenkova
Mar 9, 2017·Leukemia & Lymphoma·Driss ChaouiAlain Delmer
Feb 6, 2017·International Journal of Hematology·Yoshiaki OgawaUNKNOWN Japanese Bendamustine CLL Study Group
Jun 20, 2020·Expert Opinion on Investigational Drugs·Fortunato MorabitoManlio Ferrarini
Oct 23, 2020·Annals of Oncology : Official Journal of the European Society for Medical Oncology·B EichhorstUNKNOWN ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org